5 Noteworthy Cardiovascular Studies from American Heart Month

News
Slideshow

Psoriasis medication for heart disease prevention, the role of artificial sweeteners in different types of stroke, and 3 other noteworthy findings from American Heart Month. 

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Cardiovascular Health Maintained Over Time Linked to Reduced Risk of Neurodegenerative Disease, Study Suggests / image credit American Heart Association

Cardiovascular Health Maintained Over Time Linked to Reduced Risk of Neurodegenerative Disease, Study Suggests

Grace Halsey
March 13th 2025
Article

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

Sydney Jennings
February 28th 2025
Article

The Loss of Pulse Detection feature will begin rolling out in the US late next month.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Heart Disease Remains Leading Cause of Death in US: Daily Dose / image credit: ©New Africa/AdobeStock

Heart Disease Remains Leading Cause of Death in US: Daily Dose

Sydney Jennings
February 11th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

Patient Care Editorial Staff
February 10th 2025
Article

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

© 2025 MJH Life Sciences

All rights reserved.